Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3086PDF: 917HTML: 6618Untitled: 275Untitled: 231Untitled: 242Untitled: 257 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1422PDF: 825HTML: 369 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1254PDF: 796HTML: 1533Figure 1: 231Figure 2: 226 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2684PDF: 857HTML: 5380 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3816PDF: 949HTML: 6882 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1967PDF: 1216HTML: 340 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2133PDF: 879HTML: 262 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3601PDF: 1258HTML: 512 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3257PDF: 1675HTML: 369 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4080PDF: 797HTML: 1893 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2260PDF: 1637HTML: 687 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1106PDF: 1069Suppl. Files: 670HTML: 195 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7912PDF: 2502HTML: 2131Table 1.: 263Table 2.: 267Table 3.: 250Table 4.: 245 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
892PDF: 446HTML: 370 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2623PDF: 1771HTML: 623 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2774PDF: 805HTML: 2330 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1539PDF: 1381HTML: 119 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1682PDF: 1119HTML: 488 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1261PDF: 872HTML: 3418 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1630PDF: 1161HTML: 267 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2206PDF: 1367HTML: 3516 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1381PDF: 1104HTML: 439 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1207PDF: 635Suppl. Files: 149HTML: 502







